267 related articles for article (PubMed ID: 20615494)
1. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.
Feifel D; Macdonald K; Nguyen A; Cobb P; Warlan H; Galangue B; Minassian A; Becker O; Cooper J; Perry W; Lefebvre M; Gonzales J; Hadley A
Biol Psychiatry; 2010 Oct; 68(7):678-80. PubMed ID: 20615494
[TBL] [Abstract][Full Text] [Related]
2. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia.
Pedersen CA; Gibson CM; Rau SW; Salimi K; Smedley KL; Casey RL; Leserman J; Jarskog LF; Penn DL
Schizophr Res; 2011 Oct; 132(1):50-3. PubMed ID: 21840177
[TBL] [Abstract][Full Text] [Related]
3. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.
Lee MR; Wehring HJ; McMahon RP; Linthicum J; Cascella N; Liu F; Bellack A; Buchanan RW; Strauss GP; Contoreggi C; Kelly DL
Schizophr Res; 2013 Apr; 145(1-3):110-5. PubMed ID: 23415472
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.
Feifel D; Macdonald K; Cobb P; Minassian A
Schizophr Res; 2012 Aug; 139(1-3):207-10. PubMed ID: 22682705
[TBL] [Abstract][Full Text] [Related]
5. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
6. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
7. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
Leiderman E; Zylberman I; Zukin SR; Cooper TB; Javitt DC
Biol Psychiatry; 1996 Feb; 39(3):213-5. PubMed ID: 8837983
[No Abstract] [Full Text] [Related]
8. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
9. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
[TBL] [Abstract][Full Text] [Related]
10. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial.
Terevnikov V; Stenberg JH; Joffe M; Tiihonen J; Burkin M; Tchoukhine E; Joffe G
Hum Psychopharmacol; 2010 Aug; 25(6):431-8. PubMed ID: 20737516
[TBL] [Abstract][Full Text] [Related]
11. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
[TBL] [Abstract][Full Text] [Related]
12. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
13. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
14. ICI 204,636: a new atypical antipsychotic drug.
Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
[No Abstract] [Full Text] [Related]
15. A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia.
Guastella AJ; Ward PB; Hickie IB; Shahrestani S; Hodge MA; Scott EM; Langdon R
Schizophr Res; 2015 Nov; 168(3):628-33. PubMed ID: 26150070
[TBL] [Abstract][Full Text] [Related]
16. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
[TBL] [Abstract][Full Text] [Related]
17. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
Reschke RW
Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive clonazepam in the treatment of chronic schizophrenia.
Herrera JM; Alvarez WA; Freinhar JP; Lawson WB; Sramek JJ
Int J Psychosom; 1991; 38(1-4):17-20. PubMed ID: 1685726
[TBL] [Abstract][Full Text] [Related]
19. Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.
Lee MR; Wehring HJ; McMahon RP; Liu F; Linthicum J; Verbalis JG; Buchanan RW; Strauss GP; Rubin LH; Kelly DL
Schizophr Res; 2016 Apr; 172(1-3):165-8. PubMed ID: 26879587
[TBL] [Abstract][Full Text] [Related]
20. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.
Gallagher P; Watson S; Smith MS; Ferrier IN; Young AH
Biol Psychiatry; 2005 Jan; 57(2):155-61. PubMed ID: 15652874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
